




BREAKING NEW GROUND IN EPILEPSY

24/7 EEG™ SubQ A new way forward in epilepsy care



Want to learn more?

Contact us at uneeg@uneeg.com
or visit us at uneeg.com

UNEEG medical A/S
Borupvang 2, DK-3450 Allerød



References

1) Picot et al., Epilepsia 2008; 49(7):1230-1238. 2) Kwan et al., N Engl. J. Med. 2000;342: 314-319. 3) Salomon et al., Lancet 2012; 380: 2129-43. 4) Viana et al., Ann. Clin. Transl. Neurol., 2020; 288-293. 5) Weisdorf et al., Epilepsia 2019;60 (11):2204-2214. 6) Data on file 1. 7) Dunn-Henriksen et al., Epilepsy action, 53, 2019. 8) Hoppe et al., Arch. Neurol. 2007;1595-9. 9) Weisdorf et al., Case Rep. Neurol. Med. 2020. 10) Adan et al., Clin Med (Lond). 2020. 11) Klein et al., Neurology 2020; 903-904. 12) Karoly et al., Nat. Rev. Neurol. 2021;267-84. 13) Viana et al. Epilepsia. 2021; 00:1-9. 14) Data on file 2. 15) Golay et al., Journal of medicine & the person. 2007. 16) Richardson Epilepsy today 2019; 143. 17) Duun-Henriksen J. et al. J Sensors Vol. 2015

UNEEG™ EpiSight is a registered trademark owned by UNEEG medical A/S. Legal manufacturer: AIT Austrian Institute of Technology GmbH.

UNEEG™ medical

UNEEG™ medical

Reliable seizure tracking
Supporting treatment optimisation



© 2021 UNEEG medical A/S. All rights reserved / MKT00085-2


CE First CE-marked wearable device for
ultra long-term subcutaneous EEG recording

247™
EEG SubQ

24/7 EEG™ SubQ solution with automated data infrastructure

Real life
15 months

Hospital
Data on demand



Breaking new ground in epilepsy

Over 30 percent of people with epilepsy struggle to get their seizures under control: their quality of life is among the lowest when compared with other health conditions.¹⁻³ A real challenge for management is the unreliability of seizure diaries, which currently serve as a key tool in guiding treatment.

Ultra long-term, objective seizure tracking represents a new way forward for epilepsy care, and complements the tools currently available.

The 24/7 EEG™ SubQ solution allows for continuous EEG monitoring day and night for up to 15 months. The subcutaneous implant and external recorder, combined with a complete data-infrastructure and analytics software, provide automated seizure detection.

Detect treatment effect with objective seizure counting

- Reliable measurement of treatment effect
- Rapid, automated analysis
- On-demand EEG data access

Manage your patients remotely

- Ambulatory monitoring alleviates COVID-19 challenges
- Geographical barriers are removed
- Proven high adherence rate⁴⁻⁶

Empower patients

- New insights with real-life data
- Motivate patients

Identify seizure cycles

- Ultra long-term EEG monitoring
- High data quality over time



BREAKING NEW GROUND IN EPILEPSY

Detect treatment effect with objective seizure counting

Unrecognised seizures often stand in the way of accurate self-reporting, and can conceal the true effect of medication.⁷⁻⁹

The 24/7 EEG™ SubQ solution reliably monitors the effect of treatment by tracking the number of electrographic seizures. Changes can be observed over months, allowing the seizure burden to be followed when titrating medication over longer periods of time.

Patients' EEG data are continuously sent to the hospital by the cloud-based solution UNEEG™ MyConnect, and are automatically analysed within minutes by the UNEEG™ EpiSight software, which highlights suspected seizure events for quick expert review. The reporting tool in UNEEG™ EpiSight Analyzer conveniently displays EEG results in an easy-to-read report.

On-demand access to patient EEG data gives you the flexibility to assess the treatment effect on seizure activity – at your convenience.





BREAKING NEW GROUND IN EPILEPSY

Manage your patients remotely

The movement towards telehealth in neurology, already well established, has only accelerated under the COVID-19 pandemic.^{10,11}

The 24/7 EEG™ SubQ solution is well suited for telehealth, as it offers ambulatory EEG monitoring with a continuous transfer of data to the hospital; visits to the hospital are not needed during monitoring. In addition to working well under COVID-19, this solution can also remove potential geographical barriers between patients and hospitals.

To encourage high patient compliance, we have designed the patient interface to be very simple and user friendly. The solution includes a small, discrete wearable recorder and a tablet that automatically sends patient data to the hospital once a day.

User adherence is high, as was demonstrated in a case study where the patient recorded an average of over 20 hours per day over 230 days.⁴ The same high adherence rate was seen in a three-month study where patients recorded an average of 18.3 hours per day. All of which underscores patient acceptance of the 24/7 EEG™ SubQ solution.^{5,6}



Empower patients

Accurate seizure counting is a challenge when using other tools currently available. The uncertainty of treatment effectiveness can be frustrating for both doctor and patient.^{4,15,16}

The 24/7 EEG™ SubQ solution enables real-life seizure monitoring. Doctor and patient can now obtain objective data on electrographic seizures and real-life triggers.

Patients can go on living their regular lives without feeling constrained in their everyday activities, while the 24/7 EEG™ SubQ solution collects objective seizure data and automatically sends it to the hospital.

The new insights provided by ultra long-term EEG data have the potential to empower the patient, support buy-in to management plans and improve the doctor-patient dialogue.



BREAKING NEW GROUND IN EPILEPSY

Identify seizure cycles

Evidence indicates that multidien cycles are present in as many as 60 percent of patients with focal epilepsy. These cycles will not be detected with current scalp EEG options due to short recording timeframes.¹² Subcutaneous EEG has now made this option a reality.

In a 230-day case study from King's College London, ultra long-term EEG monitoring revealed two seizure risk cycles: the circadian cycle was visible in both EEG and diary data, while the multiday cycle was visible only in the EEG data (Figure 1).⁴

The EEG signal quality provided by the 24/7 EEG™ SubQ solution is maintained over months (Figure 2).¹³ High signal quality is demonstrated with low impedance and high stability.^{13,17}

These results reinforce that subcutaneous EEG technology is suitable for counting seizures over long periods of time, thus uncovering seizure fluctuations and seizure risk cycles in patients.¹³




Figure 1. Adapted from Viana et al., Ann. Clin. Transl. Neurol., 2020. Polar histograms of subcutaneous EEG seizures (blue) and diary events (black outline) distributed over the significant sqEEG* seizure cycles (24 hours and 5 days). Concentric rings represent the number of events/seizures.⁴
*Subcutaneous EEG

■ Subcutaneous EEG data events
— Diary events
○ Number of events




Figure 2. Adapted from Viana et al. Epilepsia, 2021

Top: dark blue line, blue shaded and grey shaded areas represent the mean, standard error, and range of daily impedance measurements for each subject, respectively.

Bottom: size of the impedance measurements database as it evolves over time, depending on the recording duration of each subject.¹⁴

Benefits of the 24/7 EEG™ SubQ solution

A breakthrough in the epilepsy management toolbox is now a reality. Ultra long-term monitoring with 24/7 EEG™ SubQ could enable you to:


- Detect treatment effect with objective seizure counting
- Manage your patient remotely
- Identify seizure cycles
- Empower your patient



24/7 EEG™ SubQ solution with automated data infrastructure

UNEEG™ SubQ

Subcutaneous implant measures EEG for up to 15 months.



24/7 EEG™ SubQ

External recorder for capturing data and powering the implant.



UNEEG™ MyConnect

Tablet for wireless data transfer, from patient to hospital.



UNEEG™ Cloud

Cloud-based solution for transferring data from patient to hospital.



UNEEG™ ProConnect

Local host software for receiving and storing data at the hospital.



UNEEG™ EpiSight Analyzer

Review system for EEG data. Highlights suspected seizures for quick expert review, and provides a report with results.

